One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition.
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.
“Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled ‘orphan diseases.’ We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases,” said Misagh Naderi, one of the paper’s lead authors and a doctoral candidate in the LSU Department of Biological Sciences.
This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.
“In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson’s disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease,” said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.
Learn more: Researchers Computationally Find the Needle in a Haystack to Treat Rare Diseases
The Latest on: Drug repositioning
[google_news title=”” keyword=”drug repositioning” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]via Google News
[/vc_column_text][/vc_column]
The Latest on: Drug repositioning
- Algorae harnessing AI to meet acute medical needson April 28, 2024 at 6:54 pm
Algorae Pharmaceuticals is looking at how using AI for drug discovery and development can help benefit the future health and wellness of society.
- What to Do About Your Bunionson April 24, 2024 at 6:50 am
She had painful bunions on both feet and had started to have trouble handling daily chores on her farm in Missouri. Plus, she didn’t like how they looked. “When I went to the pool or the beach and ...
- What Is Drug Repurposing And Why Is It A Game-Changer In Regenerative Medicine?on April 23, 2024 at 7:55 am
Repurposed drugs have already undergone rigorous testing for safety and efficacy in other medical conditions. It enables researchers to fast-track their investigations, saving time and resources.
- Drug Repurposing Market Projected to Reach USD 51.8 Billion by 2033, Driven by 4.5% CAGR | Market.uson April 22, 2024 at 11:59 pm
According to a recent report by Market.us, the Global Drug Repurposing Market size is expected to be worth around USD 51.8 Billion by 2033 from USD 32.1 Billion in 2023, growing at a CAGR of 4.5% ...
- Which ASX companies are resurrecting abandoned drugs? Part 3on April 17, 2024 at 5:00 pm
Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of ...
- Melior Discovery Earns Prestigious 'CRO of the Year' Title from Life Sciences Reviewon March 26, 2024 at 5:02 am
This approach, known as drug repositioning, can dramatically reduce the time and cost associated with bringing treatments to market. Additionally, Melior’s specialized platforms, immuno ...
- Repurposed drug shows promise against endometriosis-related pain in animal modelon March 18, 2024 at 2:16 pm
More information: Tomiko T. Oskotsky et al, Identifying therapeutic candidates for endometriosis through a transcriptomics-based drug repositioning approach, iScience (2024). DOI: 10.1016/j.isci.
- Song secures $2.89-million grant to study drug repositioning for Alzheimer’s diseaseon June 29, 2023 at 1:46 pm
Yuhua Song, Ph.D., a professor in the Department of Biomedical Engineering, has been awarded an R01 grant from the National Institutes of Health’s National Institute on Aging funding her research on ...
- How digital twins of human cells are accelerating drug discoveryon April 11, 2022 at 9:28 am
Drug repositioning partnerships are one of several ways that researchers can work with DeepLife. The simplest option is the Datastore marketplace, which allows users to access organ omics atlases.
- AI Driven Repositioning and Repurposing Summit 2021on November 26, 2020 at 4:00 pm
Given these circumstances, drug repositioning and repurposing has appeared as an alternative tool to accelerate drug development processes by seeking new indications for approved/shelved drugs ...
via Bing News